SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ShapeShift is a decentralized, multichain cryptocurrency platform that empowers users to swap, track, buy, and earn with over 30,000 assets across the top blockchains such as Bitcoin, Ethereum, Dogecoin, Cosmos, and more. The platform emphasizes financial sovereignty and self-custody, providing an open-source environment where users can engage with the most popular crypto tools and services to trade, earn, and hodl their digital assets. FOX token holders can submit and vote on proposals, helping to shape the future of ShapeShift.

ShapeShift FOX Token

ShapeShift FOX Token is experiencing intense community speculation as investors monitor its low market capitalization and circulating supply, comparing its potential to industry peers like Uniswap. Traders are actively debating whether to accumulate during current price consolidation in anticipation of a broader altcoin market breakout, fueled by long-term holders highlighting its utility and potential for significant upside during the upcoming bull cycle.

FUST (Fusion token) is the companion token of FUSD - with tokenomics which mirror those of a typical cryptocurrency. FUST can be placed in the FUST Fusion Miner and used to mine free FUSD. FUST has tokenomics which mirror those of a typical cryptocurrency, and allows those Degens who buy into the FUSD philosophy - but who also enjoy the thrill of chasing fast green candles - to make their play within the structure of the FUSD ecosystem and benefit from the best of both worlds; the possibility of a fast ride upwards whilst earning a passive income paid in our appreciating stable token courtesy of their FUST bag.

FUST Token

The FUST ecosystem is gaining momentum as investors emphasize its focus on passive yield generation through an appreciating stablecoin model. Community members are actively discussing the protocol's design, which aims to provide consistent growth that contrasts with the stagnant nature of traditional, non-yielding stablecoins.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

The community is actively debating the sustainability of Bitcoin, with many investors using $BITI as a hedging tool or a speculative play against what they perceive as a bubble. Discussion centers on high leverage, institutional manipulation, and skepticism toward the "digital gold" narrative as traders monitor technical support levels and broader market volatility.

Cintas Corp. engages in the provision of corporate identity uniforms through rental and sales programs. It operates through the following segments: Uniform Rental and Facility Services, First Aid and Safety Services, and All Other. The Uniform Rental and Facility Services segment consists of the rental and servicing of uniforms and other garments including flame resistant clothing, mats, mops and shop towels, and other ancillary items. The First Aid and Safety Services segment includes first aid and safety products and services. The All Other segment contains fire protection services and its direct sale business. The company was founded by Richard T. Farmer in 1968 and is headquartered in Cincinnati, OH.

Cintas Corporation

Cintas Corporation is experiencing significant market activity following a definitive agreement to acquire UniFirst in a $5.5 billion cash-and-stock deal, a move that the community is closely analyzing for potential regulatory hurdles and synergy realization. Investors are actively debating the long-term strategic value of this consolidation in the uniform and facility services sector, while weighing the risks associated with the deal's financing and the integration of these two major competitors.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE community is driving momentum for their project by emphasizing its status as an OG meme from the early 2000s, actively rebuilding the classic comic-making culture on the Solana blockchain. Supporters are rallying behind the ticker with a consistent daily grind, framing it as a long-term conviction play that rejects the rise of transient, forced meme tokens.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as the community highlights its role in decentralized AI infrastructure, particularly as market attention focuses on the upcoming supply halving and the network's unique utility in machine learning. Investors are actively discussing the project's long-term potential as a 'Bitcoin of AI,' while simultaneously navigating end-of-week volatility and the ongoing performance of various subnets.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing significant community buzz driven by anticipation surrounding the upcoming sentencing of co-founder Do Kwon and persistent calls for increased token burns to drive value. Investors are actively debating the potential for a long-term recovery, with many leveraging staking and ecosystem projects to signal their commitment to the chain despite broader market volatility.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is experiencing significant market interest driven by rumors of a major collaboration with the Polygon network and an integration with ACH, which community members view as a vital boost to its long-term utility. Investors are actively watching the 'OG privacy coin' for a potential rally, drawing comparisons to Zcash as they hope for a broader resurgence in privacy-focused tokens.

Diageo Plc engages in the production and distribution of alcoholic beverages. The firm brands include Johnnie Walker, Crown Royal, J&B and Buchanan’s whiskies, Smirnoff, Ciroc and Ketel One vodkas, Captain Morgan, Baileys, Don Julio, Casamigos, Tanqueray, and Guinness. It operates through the following geographical segments: North America, Europe, Asia Pacific, Latin America and Caribbean, Africa, and Corporate and Other. The company was founded on October 21, 1886 and is headquartered in London, the United Kingdom.

Diageo plc - ADR

Diageo plc

Diageo is facing significant downward pressure as market sentiment shifts amid concerns over global consumer spending, inflationary headwinds, and the impact of new U.S. tariff threats on imported spirits. While some investors view the current stock price as an attractive value entry point for a defensive blue-chip brand, the community remains divided, with many citing long-term structural challenges like changing generational habits and leadership uncertainty as reasons to remain cautious.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals is attracting investor interest following strong clinical data for zanidatamab in treating HER2-positive biliary tract cancer and progress in its oncology pipeline, fueling ongoing speculation about potential M&A activity. Market participants are also actively monitoring the company's financial performance and patent litigation updates, which remain key variables in the stock's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry...

AN2 Therapeutics Stock Cools Off After 90% Rally

AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.read more...

Power Hour Surge: Biotech Cash Floods, Energy Breakouts, and AI Bets Drive the Stocks to Watch into the Close

As Wall Street heads into the final stretch of the trading day, capital flows into biotech financing, clean energy, and emerging technology platforms are shaping the stocks traders are watching most closely into the close and after-hours session. $EONR, $SAFX, $KBLB, $HIMS, $MDCX, $ANTX, $NVO, $MDCX, $RLMD, $SLDB, $ANTX, $EDIT, $DDD

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced a $40 million private placement financing.read more...

<ul class="summary-bullets"><li>AN2 Therapeutics is expected to sell more than eight million shares of common stock at $2.85 per share.</li><li>The private placement includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital.</li><li>The stock has gained more than&nbsp;500% over four sessions since the company announced positive results for its blood cancer treatment.</li></ul>Shares of AN2 Therapeutics (ANTX) surged more than 110% on Monday, after the clinical-stage biopharmaceutical company announced that it signed a securities purchase agreement for a private placement expected to raise about $40 million in gross proceeds.<a href="https://stocktwits.com/symbol/ANTX">ANTX shares</a> recorded their biggest-ever intraday gains.As part of the deal, AN2 Therapeutics will sell 8.25 million shares of common stock at $2.85 per share, which was also the stock’s closing price on Friday. The company also offered investors the option to purchase pre-funded warrants to acquire up to 5.79 million additional shares at nearly the same price, with an exercise price of&nbsp;$0.00001 per share.The private placement is expected to close on March 10, 2026, and includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital, along with other new and existing shareholders. AN2 Therapeutics did not disclose how it plans to use the proceeds from the offering.<h2 class="st-heading-2">500% Rally After Epetraborole Update</h2>The stock has been on an extraordinary rally, adding nearly 500% over four sessions since the company announced plans to further develop its drug epetraborole into a Phase 2 proof-of-concept study for patients with Polycythemia Vera (PV) who rely on phlebotomy treatments.PV is a blood cancer that causes the bone marrow to produce too many red blood cells, increasing the risk of serious complications such as blood clots.Last week, AN2 Therapeutics said that its oral epetraborole produced consistent and sustained reductions in hematocrit across several studies involving healthy volunteers and other patient groups. The company expects to begin the Phase 2 study in the third quarter of 2026 and plans to provide initial trial updates by the following quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ANTX_jpg_31ad151992.webp" alt="ANTX.jpg">One user highlighted the various resistance levels, speculating that the stock could climb as high as $108.<stembedurl>https://stocktwits.com/M105/message/647014265</stembedurl>However, another expressed confusion over the “bullish excitement.”<stembedurl>https://stocktwits.com/Tradeforlosses/message/647018987</stembedurl>Year-to-date, the stock has gained more than 400%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iran-warns-of-crude-hitting-200-a-barrel-if-energy-infrastructure-is-targeted-report/cZdVpreRIIr">Iran Warns Of Crude Hitting $200 A Barrel If Energy Infrastructure Is Targeted: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Equity

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has...

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to...

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder...

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug...

AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?

AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

ANTX
AN2 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANTX News

ANTXAN2 Therapeutics Inc